AIDS commentary. Toxoplasmic encephalitis.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000913:Antibodies, Protozoan / Q000032:analysis; D000963:Antimetabolites / Q000627:therapeutic use; D001707:Biopsy, Needle; D001921:Brain / Q000473:pathology; D004660:Encephalitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology; D014123:Toxoplasmosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*
D000900:Anti-Bacterial Agents; D000913:Antibodies, Protozoan; D000963:Antimetabolites; D007376:Interleukin-2; D011994:Recombinant Proteins; D013411:Sulfadiazine; D007371:Interferon-gamma; D011739:Pyrimethamine